We first validated RAS pathway activation in a panel of TPM cancer cell lines by determining the level of phosphorylated ERK1 and ERK2 (pERK), aiming to document the frequent association of TPMs with elevated RAS signaling. The gene discussed is MAPK3; the disease is cancer.